Kaloba Eps 7630
Kaloba EPs 7630 Helps fight winter ailments, ills and chills. Stop the cold before it takes hold. Kaloba is the number 1 cold medication in Germany. Kaloba treats the cause of the infection and shortens the duration of the illness. Kaloba shields the linings of the airway with a protective film from viruses and bacterial, hence helping to prevent an infection. Kaloba activates the body's own immune system so that attacking viruses can be fended off. Kaloba helps prevent the growth of bacteria which have penetrated the body, thereby helping to avoid a bacterial infection. Kaloba promotes excretion of sputum or phlegm and ease coughing. Kaloba is clinically proven effective for the entire family including children from 1 year and above. Best results are achieved if this is taken at the first sign of feeling unwell - for example when that niggle is first felt in the back of the throat. 50ml
A recent scientific study conducted in Germany concluded that use of this plant extract can decrease overall symptoms of acute bronchitis, when compared with a placebo, and these symptom reductions occur within 3 to 7 days.
Kaloba is clinically proven effective for the entire family including children from 1 year and above. Provides effective relief for cold symptoms. Kaloba reduces the severity of symptoms such as congestion, cough, headache, hoarseness, minor aches and sore throat. Kaloba works best when taken at the earliest sign of symptoms. Helps fight winter ailments. Assists the body to utilise its natural defences. Assists the upper respiratory tract respond promptly against the attacks of winter ailments, ills and chills. Soothes the throat, nose and sinuses. Assists the bodys natural response to maintain free airways. helps the body to maintain optimum health when dealing with winter ailments, ills and chills.
Acute Upper Respiratory infections: Adults and children over 12 years: 7.5ml three times a day. Children 6-12 years: 5ml three times a day. Children 1-5 years of age: 2.5ml three times a day.
Duration of Intake: After the symptoms subside, it is recommended to continue treatment for several days in order to prevent relapse.
Overdose: Symptoms from over dosed have not been reported up to the present.
Missed Dose: Do not take twice the dose if you have forgotten to take Kaloba®, continue the treatment as prescribed by your health care professional or as indicated in the product insert.
Best results are achieved if it is taken at the first sign of feeling unwell - for example when that niggle is first felt in the back of the throat.
KALOBA® - Evidence Based Therapy. As the 1st line therapy in the treatment of viral URTI (upper respiratory tract infections) Kaloba® is clinically proven in efficacy to shorten the duration of viral conditions whilst reducing the severity of accompanying symptoms. Kaloba®’s measurable benefits are substantiated by Randomized Controlled Trials (RCT) which are based on the Level of Evidence (LOB) of 1. The LOB approach is an explicit way of ranking evidence. It is used in making clinical practice recommendations, and also as a research tool.
Acute Bronchitis: Efficacy and safety of an extract of Pelargonium sidoides (EPs® 7630) in adults with acute bronchitis: A randomized, double-blind, placebo-controlled trial. * Reduction of 2 days or 30% faster recovery than placebo treated patients. * Alleviates the severity of symptoms rapidly.
Acute Sinusitis. EPs® 7630 in acute sinusitis: A multi-centre, prospective, randomised double-blind, placebo-controlled trial. * Shortens the recovery period. * Alleviates the severity of symptoms rapidly.
Common Cold. Efficacy and safety of an extract of Pelargonium sidoides (EPs® 7630) in Common Cold: A multi-center, double-blind, placebo-controlled trial. * Shortens the duration of Common Cold and the inability to work significantly. * Alleviates the severity of symptoms rapidly.
* References available.
Kaloba® - Excellent Safety Profile. Kaloba® is well tolerated by both children and adults alike. This is substantiated by randomized controlled trials and several observational studies. The overall rate of adverse events (AE) is within the same range as placebo and far lesser than antibiotics induced AE. The common AE relates to the respiratory system and the digestive system. No serious AE was documented.
The AE occurring in observation and clinical studies were observed in qualitative and quantitative terms. Doctors’ and patients’ concluding judgments on the tolerability of treatment with KALOBA® were altogether very positive. In practically every case, tolerability of treatment was stated in approximately 100% as ‘very good’ or ‘good’.
Specialists in phytopharmaceuticals. Founded in 1866, Dr William Schwabe Pharmaceuticals is the worlds leading manufacturer in its field. The company's tradition of innovative research spans more than 140 years. the success of the company in the field of plant based formulations justifies its reputation as an international specialist on the research and manufacture of phyto-based dietary supplements.
Each bottle contains: 50ml Pelargonium sidoides extract (ethanolic extract from the roots of Pelargonium sidoides) Glycerol, alcohol by volume 12%, water.
Keep out of reach of Children. There is no known drug interaction with Kaloba®. However, patients taking wafarin or anti-coagulation drug should be cautious when taking Kaloba®. Discard three months after opening. Avoid direct sunlight. Store below 30C. Do not take if: Pregnant or breast feeding. taking blood thinning medicaion. If you have severe hepatic or renal disease.